We are live on ! Find out more

EyePoint Inc

EYPT

Market cap $32.8M

0.3800 USD

+0.0026

0.69%

At close Updated Oct 29, 4:00 PM EDT

Pre-market

After hours

0.3773

-0.0027

0.71%

1 day

0.69%

5 days

-9.52%

1 month

-88.89%

3 months

-96.81%

6 months

-97.05%

Year to date

-97.83%

1 year

-96.76%

5 years

-96.69%

10 years

-98.17%

About: EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.

Employees: 214

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 6.7%

Neutral 78.3%

Negative 15%

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT

NEW YORK, Oct. 29, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of EyePoint, Inc. ("EyePoint" or the "Company") (NASDAQ: EYPT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT

Zacks Investment Research

EyePoint (EYPT) Expected to Beat Earnings Estimates: Should You Buy?

EyePoint (EYPT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

EyePoint (EYPT) Expected to Beat Earnings Estimates: Should You Buy?

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT

NEW YORK, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of EyePoint, Inc. (“EyePoint” or the “Company”) (NASDAQ: EYPT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT

EyePoint Pharmaceuticals (EYPT) Securities Investigation Notice - Levi & Korsinsky

EyePoint Pharmaceuticals shareholders lost nearly 67% of their share value in a single session after the Phase 3 LUCIA topline readout. Levi & Korsinsky is investigating potential securities law violations on behalf of EYPT shareholders who lost money EyePoint Pharmaceuticals shareholders lost nearly 67% of their share value in a single session after the Phase 3 LUCIA topline readout. Levi & Korsinsky is investigating potential securities law violations on behalf of EYPT shareholders who lost money

EyePoint Pharmaceuticals (EYPT) Securities Investigation Notice - Levi & Korsinsky

Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving EyePoint Pharmaceuticals (EYPT)

DURAVYU's Phase 3 LUCIA trial missed its primary endpoint and EYPT shares lost nearly 80% of their value in a single session. Levi & Korsinsky is investigating on behalf of shareholders who may have legal rights arising from those losses DURAVYU's Phase 3 LUCIA trial missed its primary endpoint and EYPT shares lost nearly 80% of their value in a single session. Levi & Korsinsky is investigating on behalf of shareholders who may have legal rights arising from those losses

Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving EyePoint Pharmaceuticals (EYPT)

EYPT SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving EyePoint Pharmaceuticals

EyePoint described its Phase 3 wet AMD trials as designed in close alignment with the FDA. LUCIA then missed its primary endpoint, and LUGANO's favorable result depended on excluding nine DURAVYU patients.

EYPT SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving EyePoint Pharmaceuticals

EyePoint Pharmaceuticals Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into EyePoint Pharmaceuticals (EYPT)

EyePoint Pharmaceuticals shares lost nearly 80% of their value following the disappointing Phase 3 LUCIA trial results for DURAVYU in wet age-related macular degeneration. Levi & Korsinsky is investigating potential securities law violations on behalf of EYPT shareholders who lost money.

EyePoint Pharmaceuticals Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into EyePoint Pharmaceuticals (EYPT)

EyePoint Slashing Workforce, Halting Clinical Trials to Pivot Focus

EyePoint Inc. (NASDAQ:EYPT) is slashing its workforce by 53% and halting wet age-related macular degeneration clinical trials early following disappointing Phase 3 results.

EyePoint Slashing Workforce, Halting Clinical Trials to Pivot Focus

EyePoint, Inc. (EYPT) Discusses LUCIA Phase III Topline Results for DURAVYU in Wet Age-Related Macular Degeneration Prepared Remarks Transcript

EyePoint, Inc. (EYPT) Discusses LUCIA Phase III Topline Results for DURAVYU in Wet Age-Related Macular Degeneration Prepared Remarks Transcript

EyePoint, Inc. (EYPT) Discusses LUCIA Phase III Topline Results for DURAVYU in Wet Age-Related Macular Degeneration Prepared Remarks Transcript

This Biotech Stock Sinks Below $1 After Key Eye Drug Fails and Staff Is Slashed. Why There's Still Hope.

EyePoint stock is heading for its largest single-day percentage drop on record.

This Biotech Stock Sinks Below $1 After Key Eye Drug Fails and Staff Is Slashed. Why There's Still Hope.

See News Rankings

Price charts implemented using Lightweight Charts™